Amova Asset Management Americas Inc. Sells 90,468 Shares of Natera, Inc. $NTRA

Amova Asset Management Americas Inc. decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 12.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 628,594 shares of the medical research company’s stock after selling 90,468 shares during the period. Natera makes up approximately 1.0% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 28th biggest position. Amova Asset Management Americas Inc.’s holdings in Natera were worth $101,128,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Sound Income Strategies LLC boosted its position in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the last quarter. Quent Capital LLC purchased a new stake in Natera in the third quarter valued at approximately $46,000. Hilltop National Bank lifted its position in Natera by 59.8% during the third quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 116 shares during the last quarter. N.E.W. Advisory Services LLC grew its stake in Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after buying an additional 226 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Natera by 23.1% in the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock worth $69,000 after buying an additional 81 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on NTRA shares. Citigroup began coverage on shares of Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective for the company. Piper Sandler lifted their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Evercore increased their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. UBS Group raised their price objective on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $253.47.

Natera Stock Performance

NASDAQ:NTRA opened at $203.03 on Thursday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The firm has a market cap of $28.78 billion, a PE ratio of -132.70 and a beta of 1.65. The business has a 50 day moving average price of $224.59 and a 200-day moving average price of $204.76.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period in the prior year, the business posted ($0.41) EPS. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In other news, CFO Michael Burkes Brophy sold 6,939 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the transaction, the chief financial officer directly owned 52,120 shares of the company’s stock, valued at approximately $11,874,499.60. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 3,950 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $200.02, for a total value of $790,079.00. Following the transaction, the chief executive officer owned 156,607 shares of the company’s stock, valued at approximately $31,324,532.14. This represents a 2.46% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 367,669 shares of company stock valued at $85,584,453. Company insiders own 5.63% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.